We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics. Exact Sciences currently has two of the brands in cancer diagnostics, Cologuard and Oncotype DX. Cologuard Test: This is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Oncotype DX: Genomic Health's first product, the 21-gene Oncotype DX breast cancer test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients.
- Recent EXAS Stock Price: $80.93
- Yearly Gain for EXAS stock: 56.66%
- Market Cap for EXAS stock: $14.28B
- P/E Ratio for EXAS stock: -27.15
Will EXAS's stock price go up? Is there an accurate EXAS stock forecast available?
TipRanks.com reports that Exact Sciences currently has 15 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $85.00. The target pricing ranges from a high EXAS forecast of $100.00 down to a low forecast of $70.00. Exact Sciences (EXAS)’s last closing stock price was $80.93 which would put the average price target at 7.66% upside.
In addition, TradingView issued a Strong Buy rating for EXAS stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on EXAS stock.
Other analysts covering EXAS include:
- Unknown Analyst of Piper Sandler issued a Hold rating with the price target of $ 80 on 22 hours ago
- Mark Massaro of BTIG issued a Buy rating with the price target of $ 95 on 3 days ago
- Patrick B Donnelly of Citigroup issued a Buy rating with the price target of $ 100 on 4 days ago
- Puneet Souda of SVB Securities issued a Buy rating with the price target of $ 90 on 5 days ago
If you are wondering if EXAS is a good stock to buy, here are 3rd party ratings for EXAS stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 41% (103 out of 250)
What is the sentiment on the street regarding Exact Sciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for EXAS stock: Very Bullish
- Blogger Consensus for EXAS stock: Bullish
- Media Buzz for EXAS stock: Very High
- Insider Signal for EXAS stock: ―
- Investor Sentiment for EXAS stock: Negative
- Hedge Fund signal for EXAS stock: Negative
The stock market is extremely volatile, and you need to do your own research on EXAS stock including scouring the social networks like EXAS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for EXAS stock chart >>
Summary: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.
- Recent SRPT Stock Price: $157.19
- Yearly Gain for SRPT stock: 63.04%
- Market Cap for SRPT stock: $10.26B
- P/E Ratio for SRPT stock: -8.676
Will SRPT's stock price go up? Is there an accurate SRPT stock forecast available?
TipRanks.com reports that Sarepta Therapeutics currently has 22 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $170.94. The target pricing ranges from a high SRPT forecast of $206.00 down to a low forecast of $138.00. Sarepta Therapeutics (SRPT)’s last closing stock price was $157.19 which would put the average price target at 11.07% upside.
In addition, TradingView issued a Strong Buy rating for SRPT stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on SRPT stock.
Other analysts covering SRPT include:
- Neena Bitritto-Garg of Citigroup issued a Buy rating with the price target of $ 204 on 22 hours ago
- Colin Bristow of UBS issued a Buy rating with the price target of $ 173 on 22 hours ago
- Gavin Clark-Gartner of Evercore ISI issued a Buy rating with the price target of $ 173 on 22 hours ago
- Gil Blum of Needham issued a Buy rating with the price target of $ 185 on 22 hours ago
If you are wondering if SRPT is a good stock to buy, here are 3rd party ratings for SRPT stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 41% (103 out of 250)
What is the sentiment on the street regarding Sarepta Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for SRPT stock: Very Bullish
- Blogger Consensus for SRPT stock: Bullish
- Media Buzz for SRPT stock: High
- Insider Signal for SRPT stock: ―
- Investor Sentiment for SRPT stock: Positive
- Hedge Fund signal for SRPT stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on SRPT stock including scouring the social networks like SRPT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SRPT stock chart >>
Summary: agilon health inc. which partners with primary care physicians to provide healthcare services. agilon health inc. is based in CA, United States.
- Recent AGL Stock Price: $23.81
- Yearly Gain for AGL stock: 25.59%
- Market Cap for AGL stock: $10.02B
- P/E Ratio for AGL stock: -107.716
Will AGL's stock price go up? Is there an accurate AGL stock forecast available?
TipRanks.com reports that Agilon Health currently has 14 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $31.27. The target pricing ranges from a high AGL forecast of $41.00 down to a low forecast of $26.00. Agilon Health (AGL)’s last closing stock price was $23.81 which would put the average price target at 30.95% upside.
In addition, TradingView issued a Sell rating for AGL stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AGL stock.
Other analysts covering AGL include:
- Gary Taylor of TD Cowen issued a Buy rating with the price target of $ 29 on 3 days ago
- Adam Ron of Bank of America Securities issued a Buy rating with the price target of $ 26 on 3 days ago
- Steve Baxter of Wells Fargo issued a Buy rating with the price target of $ 28 on 4 days ago
- Michael Craig Jones of Stifel Nicolaus issued a Buy rating with the price target of $ 32 on 5 days ago
If you are wondering if AGL is a good stock to buy, here are 3rd party ratings for AGL stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 48% (119 out of 250)
What is the sentiment on the street regarding Agilon Health? (Current ratings compiled by TipRanks.com)
- News Sentiment for AGL stock: Very Bullish
- Blogger Consensus for AGL stock: Bullish
- Media Buzz for AGL stock: Medium
- Insider Signal for AGL stock: Negative
- Investor Sentiment for AGL stock: Very Negative
- Hedge Fund signal for AGL stock: Neutral
The stock market is extremely volatile, and you need to do your own research on AGL stock including scouring the social networks like AGL StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AGL stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
